31.26
-0.07(-0.22%)
Currency In USD
| Previous Close | 31.33 |
| Open | 31.06 |
| Day High | 31.6 |
| Day Low | 31.06 |
| 52-Week High | 32.21 |
| 52-Week Low | 24.05 |
| Volume | 3.38M |
| Average Volume | 3.65M |
| Market Cap | 13.89B |
| PE | 12.31 |
| EPS | 2.54 |
| Moving Average 50 Days | 27.38 |
| Moving Average 200 Days | 27.46 |
| Change | -0.07 |
If you invested $1000 in Royalty Pharma plc (RPRX) since IPO date, it would be worth $768.44 as of February 05, 2025 at a share price of $31.26. Whereas If you bought $1000 worth of Royalty Pharma plc (RPRX) shares 3 years ago, it would be worth $830.94 as of February 05, 2025 at a share price of $31.26.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Royalty Pharma Announces Sale of MorphoSys Development Funding Bonds
GlobeNewswire Inc.
Jan 29, 2025 2:00 PM GMT
Total proceeds of $530 million on $300 million original 2022 investment Proceeds strengthen balance sheet and provide added flexibility to pursue disciplined capital allocation strategy, including significant share repurchases and royalty acquisition
Royalty Pharma to Announce Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025
GlobeNewswire Inc.
Jan 28, 2025 9:15 PM GMT
NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth quarter and full year 2024 financial results on Tuesday, February 11, 2025 before the U.S. financial markets open. The comp
Royalty Pharma to Highlight Accomplishments and Provide Business Update at 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 10, 2025 12:30 PM GMT
2024 Portfolio Receipts expected to be approximately $2,800 million, at the upper end of guidance rangeExciting development-stage pipeline with potential for peak royalties of >$1.2 billion; multiple key upcoming events, including Phase 3 results for